Genopole Partnering Week 2025

The in-person event on October 14 at our partner SAFIC ALCAN‘ offices in La Défense (Tour Pacific), will be dedicated to our Startups Pitches competition and will be structured in two parts:

• Morning: “Environmental Impact” – pitch session for startups with disruptive innovations in agtech, greentech, foodtech, cosmetics, bio-ingredients, etc.
• Afternoon: “Health” – pitch session for startups specializing in the development of innovative therapies, vaccines, diagnostics, AI, etc.

Each will have 5 minutes to convince the Startup Pitches competition jury, made up of manufacturers, financiers, Genopole stakeholders, and partner support organizations.

The prize:

• Two prizes awarded by our sponsors to reward the strongest business potential and the best ability to convince, in each category.
• The two winners will receive a contribution to participate in a major international conference in their field + support from a Genopole Program Manager to increase their potential for international expansion.

🚨 Registration opening soon 🚨

Are you an investor, innovation manager, or industrialist looking for high-impact biotech projects?
Genopole Partnering Week is designed for you.
Register now to meet the startups of your choice!

Registration is free but mandatory to attend the event in La Défense and to access the online meeting platform

Venue:

October 14 | La défense – Tour Pacific
11 Cr Valmy,
92800 Puteaux – France

📍Access Map >>

Tuesday, October 14

The event will take place in the heart of La Défense, in the easily accessible premises of our partner Safic-Alcan (Tour Pacific) which features a 200-seat auditorium, confidential meeting rooms, and a large networking area with a buffet.

Wednesday, October 15 to Friday, October 17

Other opportunities for individual meetings will be available via video conference during these three days.

Register to gain access to the online meeting platform with the startups of your choice.

Already registered?
Organize your appointments now on our meeting platform!

• Investors

  

  Yves Loïc Martin, gérant | Alternative Assets Finance
  “ We have already participated in two editions of Partnering Week, and we will be there again this year.
  Why? Because on average, one out of every two projects matches our investment strategy—that’s a lot. Our areas of interest are healthcare, mainly oncology, and innovations with an impact in the energy, environment, and sustainable materials sectors. Partnering Week presents many projects on these themes. We are also interested in the maturity level of startups. We are looking for startups in the start-up or even pre-start-up phase, sometimes up to the seed round. Partnering Week gives us direct access to this type of startup, led by bold entrepreneurs, who we know are well supported by the Genopole team.”

  Constantin de Chaudenay, Senior Associate | AFI ventures
  “ We had the pleasure of participating in Genopole Partnering Week last year—and we’re delighted to be back again this year! It’s a unique event that allows us to concentrate valuable meetings with all the entrepreneurs in the program into a single day. This dynamic and direct format is ideal for going beyond the paperwork: it allows us to see, face to face, whether these often highly academic profiles also have a real entrepreneurial and commercial spirit.
  At AFI Ventures, we support impactful startups from their very first steps.
  Our ambition is to support those who are inventing concrete solutions to the major challenges of our time—whether in health, climate, energy, pollution control, decarbonization, or new ways of consuming and producing. It is precisely these themes, at the heart of Genopole’s innovation, that bring us together.“

• Corporate groups

  

  Chloé Leprêtre, Global Head R&D Search & Evaluation, R&D External Innovations | Servier
  “Genopole Partnering Week is an opportunity for us to stay informed about the development of startups supported by Genopole in the pharmaceutical field and, for our part, to share updates on our therapeutic areas. Oncology remains a key focus for Servier, which is also very interested in neurology and precision medicine supported by new artificial intelligence technologies. We are on the lookout for innovations. We know that the companies accelerated by Genopole are well established and have well-thought-out projects. That’s why we will once again be participating in Genopole Partnering Week.“.

Gilles Trystram, CEO | Genopole

“We create opportunities for the startups we support to connect with investors and industry players who can transform their breakthroughs into real-world impact. Every collaboration that emerges from Partnering Week is a step towards a greener industry and a better quality of life.”

A look back at the 2024 edition: tangible results

Last year in Paris and via video conference, more than 230 participants attended, including 46 major industrial groups and 57 investors from all over France and beyond. Face-to-face exchanges led to concrete collaborations: NDAs signed, initial commercial discussions, and more.
>>> Read more

• AGDIA EMEA

  #Ag/Clean/GreenTech
  Agdia EMEA optimizes diagnostic solutions for plant pathogens and genetically modified organisms (GMOs) based on immunological and molecular techniques.  Our dignostic kits are sensitive, reproducible, robust and reliable and are aimed at seed professionals, horticulturists, and plant diagnostic and research laboratories.

  

• AMATERA BIOSCIENCES

  #Ag/Clean/GreenTech
  Amatera Biosciences is on the mission to sustain perennial crops. To do so, our non-GMO breeding platform accelerates the natural evolution, the selection and the crossing of plants directly at a cellular level. Our first application is on coffee, before expanding to other perennial crops threatened by climate change and massive diseases, such as cacao, grapes and bananas.

  

• Auralip

  #Foodtech
  AuraLIP  : Foodtech development of a hemp-based fermented protein  ingredient

  

   

• BLUE2

  #Ag/Clean/GreenTech
  Blue2 converts the CO2 emitted by the cosmetics, pharmaceutical and chemical industries into high value-added biosourced molecules using microalgae. Carbon dioxide-rich effluent is injected into Blue2’s proprietary microalgal photobioreactor, installed at the emissions outlet. Once the CO2 has been captured, the microalgae are valorized into molecules used by the customer in its own production, while the remaining biomass is transformed into proteins and biofertilizers.

   

• CELLAVEN

  #Healthtech
  In vitro cell culture is a time consuming process, where human error is always possible. Automated cell culture solutions currently on the market are expensive (>200k eur) and complex to use. Based on patented fluid handling technology, Cellaven has developped Nestor: an easy to use and affordable (~30k eur) automated device for in vitro cell culture, targeting R&D laboratories. We are launching in Sept 2025 in 13 European countries thanks to a network of 7 distributors, and have already received orders from major pharmaceutical companies. Our next step is to raise a Serie A in 2026 in order to expand our operations to USA.

• Cgenetix

  #Diagnostic

  CGenetix is developing a new non-invasive in vitro medical device to quantify organ damage during a pathological process such as transplant rejection. Focusing first on kidney transplantation, we plan to become in the next decade one of the European leaders in cfDNA for the medical follow-up of transplant patients.

  

• EPICS BIOTECHNOLOGY

  #Ag/Clean/GreenTech

  EPICS Biotechnology is an innovative company specializing in synthetic biology, developing next-generation solutions for sustainable agriculture and bio manufacturing.
  Our mission is to harness the natural biosynthetic capabilities of plants particularly Camelina sativa to efficiently and sustainably produce high-value biomolecules at scale, using techniques such as CRISPR-Cas9 and transgenesis.

• FUNGU’IT

  #Foodtech

  Fungu’it, our mission is to make industrial food production healthier, more sustainable, and accessible by upcycling plant by-products through fermentation to create a new generation of aromas. Our unique solid-state fermentation process transforms by-products into high-value aromatic ingredients.

  We have developed ingredients for the plant-based meat market as well as for the cocoa market, with our first ingredient already commercialized.

  

• HKVOR

  #Ag/Clean/GreenTech

  HKVOR adds value to French sheep wool and human hair through green keratin extraction. We offer our extracted keratin to various markets. We are currently scaling up industrial production and are interested in commercial partnerships.

• IntegraGen member of groupe OncoDNA

  #Healthtech

  IntegraGen membre du groupe OncoDNA est spécialisée dans le décryptage du génome humain et réalise des analyses pertinentes et rapidement interprétables pour des laboratoires académiques et privés. Nous fournissons aux chercheurs et aux médecins des outils universels et individualisés de guidage thérapeutique leur permettant d’adapter le traitement au profil génétique du patient.

  

• Ispiron

  #Healthtech

  Ispiron is on a mission to decentralize, automate and streamline biologics manufacturing, a sector that is exploding in demand but stuck with complex infrastructures and processes. We are building a technological solution that will reduce production time by up to 50% and uses 40x less resources. By replacing 1,000L systems with AI-driven 25L reactors, the industry can decarbonize upstream production, localize supply chains and de-risk scale-up, all while increasing agility and productivity. For investors seeking climate-aligned innovation with commercial traction, Ispiron represents both impact and opportunity.

• MICROXPACE

  #Ag/Clean/GreenTech

  microXpace offers patented probiotic solutions specifically designed against parasitic diseases in aquaculture. Our cutting-edge technology is uniquely effective in managing sea lice infestations, a significant challenge in the salmon farming sector.

  

• MSLAB

  #Healthtech

  MSLAB manufactures oral and liquid medications dedicated notably to the treatment of chronic diseases such as type 2 diabetes. Investing in the implementation of its EU-GMP certified industrial site is a unique opportunity to enter the export market in the Middle East and Latin America in the long term thanks to already secured contracts. This investment in equipment and infrastructure of €8.5M will be profitable by 2031.

• Mycellium technologies

  #FoodTech

  MYCTECHS innovation reduces our meat consumption with tasty fungus mycelium based foods. This is achieved through our innovative technology that rehabilitates the benefits of fermentation and promotes a circular economy by giving a second life to agro by-products

  

• Nutropy

  #Foodtech

  Nutropy is a French B2B company that enables the next generation of cheese & dairy products using its precision fermentation technology. More specifically, Nutropy develops an animal-free plug & play milk replacement for large scale dairy applications. We produce milk proteins and fatty acids identical to those produced by cows to enable the production of cheeses that taste as good as conventional cheese but are more sustainable, healthier and better for the animals.

  

• ORINOVA

  #Healthtech

  ORINOVA is developing a breakthrough innovation in oncology with a patented nanomedicine incorporating a unique dual therapy: a chemotherapy molecule combined with gold nanoparticles. This combination amplifies the effect of radiotherapy, optimises the efficacy of chemotherapy and enables tumours to be targeted via intra-tumoral administration, thereby limiting side-effects for patients. This intelligent nano-object could revolutionise the treatment of particularly resistant solid tumours, such as glioblastoma. We are looking for preseed and seed investors and pharma partners for licensing.

   

• PAPILIO.BIO

  #Diagnostic #Healthtech

  Papilio.bio is developing a rapid self-test to detect HPV (human papillomavirus) infections in just 15 minutes.
  Our unique solution is based on a patented-pending technology, designed to be user-friendly, accessible, and eco-friendly. With the support of an intuitive mobile app, we guide users through result interpretation, medical guidance, and personalized follow-up.
  Papilio.bio addresses inequalities in access to screening, especially for populations far from healthcare, and is committed to the active prevention of HPV-related cancers, particularly cervical cancer.

  We are seeking partnerships in R&D, co-development, licensing, seed funding, industrialization, and commercialization to scale up our solution and deploy large-scale screening programs in collaboration with public, private, and non-profit stakeholders.

• PHAIRILAB

  #Healthtech

  PHAIRILAB innovates with unique biotechnological solutions focused on Colombian biodiversity. Our uniqueness lies in transforming natural resources into high-quality health products, principally focus on cancer patients. We seek collaborations for funding, R&D, licensing, industrialization, and commercialization of our discoveries. Together, we can revolutionize the bioeconomy and provide sustainable and effective health solutions globally. Join us in harnessing the immense potential of nature for the benefit of humanity.

• PLANTIK BIOSCIENCES

  #Ag/Clean/GreenTech

  Plantik is an AgBiotech company developing next-generation plant engineering technologies
  to create climate-resilient crops. Leveraging machine learning, genome editing, and patent-
  pending cell transformation technologies, Plantik revolutionizes how to tackle complex traits
  in plants, starting with higher tolerance to heat. Its technology applies to a growing variety of
  crops, including tomato, potato, quinoa, and hemp.

  

• POLYTHERAGENE

  #Healthtech

  Polytheragene develops and commercializes cationic polymers for (i) nucleic acids (DNA and RNA) transfer for gene therapy and bioproduction of viruses and proteins and (ii) neutral copolymers for drug delivery.

  

• PREDIDIAB

  #Diagnostic

  PREDIDIAB proposes to develop tests capable of integrating all individual, environmental and heritable factors, to predict with good accuracy the onset of type 2 diabetes in subjects still in perfect apparent health, the age of onset, the form of diabetes and its evolution. This kind of prediction will enable us to propose a personalized prevention strategy. The tests are based on several patents filed or in preparation by academic players CERITD and UMR8199.

• PROJET ZEBRAMED

  #Healthtech

  ZebraMed rescues billions in R&D by validating thousands of AI-designed hits in living organisms at industrial scale and generating the first integrative whole-body, population licensable dataset. Our TechBio platform cuts preclinical time and cost by 50 % and flags leads 60 % safer. By fusing automation, AI, and a 3Rs-compliant organism, we power internal discovery, AI training, and data licensing; delivering faster, safer drugs and durable ROI.

• SE THERAPEUTICS

  #Healthtech

  SE-Therapeutics harnesses the power of certain microbial proteins to create innovative treatments. We created Self Entering forms of CRISPR/Cas proteins that can penetrate a wide variety of cells, paving the way for a new class of gene-editing therapeutics for the cell and gene therapy industry. Our primary mission is to enable access to life saving cell therapies in the field of oncology to millions of people.

  

• So Sweet

  #FoodTech

  Produces a new generation of sweet ingredients from plant proteins extracted through an innovative process to address sugar reduction and taste improvement challenges for food manufacturers.

  

• STH BIOTECH

  #Healthtech

  STH BIOTECH unlocks the access to rare active botanical compounds using plant biotechnology and synthetic biology to develop innovative active ingredients and APIs for health and wellness industrials.
  

• SYNANTHRA

  #Ag/Clean/GreenTech

  Synanthra is pioneering a breakthrough bio-electrochemical process to produce green ammonia – an essential chemical for fertilizers, energy storage, and industrial applications. By harnessing the power of microbial engineering, we offer a scalable, sustainable alternative to traditional ammonia production.

   

• SYNAPTYS neuroscience

  #Healthtech

  SYNAPTYS neuroscience is developing an innovative therapeutic approach that could transform the lives of Alzheimer’s patients. Our solution is one of the few to meet the new recommendations of health authorities (FDA, EMA). The combination of recent concordant studies supports our development program, which is expected to be launched in humans next year.

  

• VRAI HEART

  #Healthtech

  VRAI-Heart is a medical device that relies on virtual reality enhanced by artificial intelligence, combined with motion tracking. It integrates preoperative data (e.g. imaging by scanner) and intraoperative data acquired in real-time to provide intuitive navigation and more precise and faster targeting, thereby optimizing cardiac interventional procedures.
  As a pioneer of real-time intraoperative navigation in an immersive real virtual digital twin, VRAI-Heart aims to position itself as a major player in the field.